Massachusetts-based RNAi therapeutics firm Alnylam Pharmaceuticals has announced promising results from its Phase 3 trial on a potential treatment for renal decline.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,